Wealth Enhancement Advisory Services’s Rocket Pharmaceuticals RCKT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$80.4K Sell
30,588
-60,980
-67% -$211K ﹤0.01% 3972
2026
Q2
$358K Buy
91,568
+10,700
+13% +$35.6K ﹤0.01% 3027
2026
Q1
$287K Buy
80,868
+62,638
+344% +$249K ﹤0.01% 2821
2025
Q4
$64.5K Buy
18,230
+1,102
+6% +$3.77K ﹤0.01% 3504
2025
Q3
$53.8K Buy
+17,128
New +$53.9K ﹤0.01% 3418

Other funds holding RCKT

Wealth Enhancement Advisory Services's RCKT Position: Q3 2026 in Review

Wealth Enhancement Advisory Services reduced its Rocket Pharmaceuticals (RCKT) stake by 67% in Q3 2026, selling an estimated $211K and leaving 30,588 shares worth $80.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3972.

Wealth Enhancement Advisory Services first reported a position in RCKT in Q3 2025 and has held it in 5 quarters since. The position peaked at $358K in Q2 2026. 173 funds tracked by Wall St. Rank hold RCKT as of Q3 2026.

  • Wealth Enhancement Advisory Services held 30,588 shares of Rocket Pharmaceuticals worth $80.4K as of Q3 2026.
  • Wealth Enhancement Advisory Services sold 60,980 Rocket Pharmaceuticals shares in Q3 2026, an estimated $211K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #3972 holding.
  • Wealth Enhancement Advisory Services first reported a position in Rocket Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • Wealth Enhancement Advisory Services's Rocket Pharmaceuticals position peaked at $358K in Q2 2026.
  • 173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.